
SUBSTITUTE HOUSE BILL 1553

State of Washington

60th Legislature

2007 Regular Session

By House Committee on Health Care & Wellness (originally sponsored by Representatives Hinkle, Morrell, Moeller, Seaquist, Curtis, Linville, Green and Ormsby)

READ FIRST TIME 02/26/07.

1 AN ACT Relating to a controlled substances prescription monitoring
2 program; reenacting and amending RCW 42.56.360; adding a new chapter to
3 Title 69 RCW; and prescribing penalties.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 NEW SECTION. **Sec. 1.** The legislature finds that prescription drug
6 abuse has been on the rise and that often dispensers and prescribing
7 providers are unaware of prescriptions provided by others both in and
8 out of state.

9 It is the intent of the legislature to establish an electronic
10 database available in real time to dispensers and prescribers of
11 controlled substances. And further, that the department in as much as
12 possible should establish a common dataset with other sets of other
13 states.

14 NEW SECTION. **Sec. 2.** The definitions in this section apply
15 throughout this chapter unless the context clearly requires otherwise.

16 (1) "Controlled substance" has the meaning provided in RCW
17 69.50.101.

18 (2) "Department" means the department of health.

1 (3) "Patient" means the person or animal who is the ultimate user
2 of a drug for whom a prescription is issued or for whom a drug is
3 dispensed.

4 (4) "Dispenser" means a person who delivers a Schedule II, III, IV,
5 or V controlled substance to the ultimate user, but does not include:

6 (a) A practitioner or other authorized person who administers, as
7 defined in RCW 69.41.010, a controlled substance; or

8 (b) A licensed wholesale distributor or manufacturer, as defined in
9 chapter 18.64 RCW, of a controlled substance.

10 NEW SECTION. **Sec. 3.** (1) The department shall establish and
11 maintain a web-based interactive prescription monitoring program
12 available in real time to monitor the prescribing and dispensing of all
13 Schedules II, III, IV, and V controlled substances and any additional
14 drugs identified by the board of pharmacy as demonstrating a potential
15 for abuse by all professionals licensed to prescribe or dispense such
16 substances in this state. As much as possible, the department should
17 establish a common database with other states.

18 (2) Except as provided in subsection (5) of this section, each
19 dispenser shall submit to the department by electronic means
20 information regarding each prescription dispensed for a drug included
21 under subsection (1) of this section. Drug prescriptions for more than
22 immediate one day use should be immediately reported. The information
23 submitted for each prescription shall include, but not be limited to:

24 (a) Patient identifier;

25 (b) Drug dispensed;

26 (c) Date of dispensing;

27 (d) Quantity dispensed;

28 (e) Prescriber; and

29 (f) Dispenser.

30 (3) Each dispenser shall immediately submit the information in
31 accordance with transmission methods established by the department.

32 (4) The department may issue a waiver to a dispenser that is unable
33 to submit prescription information by electronic means; however, all
34 dispensers shall be required to submit prescription information by
35 electronic means within one year from the effective date of this act.
36 The waiver may permit the dispenser to submit prescription information

1 by paper form or other means, provided all information required in
2 subsection (2) of this section is submitted in this alternative format.

3 (5) The data submission requirements of this section do not apply
4 to:

5 (a) Medications provided to patients receiving inpatient services
6 provided at hospitals licensed under chapter 70.41 RCW; or

7 (b) Pharmacies operated by the department of corrections for the
8 purpose of providing medications to offenders in prison or in a work
9 release program that is receiving pharmaceutical services from a
10 department of corrections pharmacy.

11 (6) The department shall seek federal grants to support the
12 activities described in this act. As state and federal funds are
13 available, the department shall develop and implement the prescription
14 monitoring program. The department may not require a practitioner or
15 a pharmacist to pay a fee or tax specifically dedicated to the
16 operation of the system.

17 (7) The department shall report to the legislature on the
18 implementation of this chapter by December 1, 2009.

19 NEW SECTION. **Sec. 4.** (1) Prescription information submitted to
20 the department shall be confidential, in compliance with the federal
21 health insurance portability and accountability act of 1996 and its
22 implementing regulations, and not subject to disclosure, except as
23 provided in subsections (3), (4), and (5) of this section.

24 (2) The department shall maintain procedures to ensure that the
25 privacy and confidentiality of patients and patient information
26 collected, recorded, transmitted, and maintained is not disclosed to
27 persons except as in subsections (3), (4), and (5) of this section.

28 (3) The department shall review the prescription information. The
29 department shall notify the practitioner and allow explanation or
30 correction of any problem. If there is reasonable cause to believe a
31 violation of law or breach of professional standards may have occurred,
32 the department shall notify the appropriate law enforcement or
33 professional licensing, certification, or regulatory agency or entity,
34 and provide prescription information required for an investigation.

35 (4) The department may provide data in the prescription monitoring
36 program to the following persons:

1 (a) Persons authorized to prescribe or dispense controlled
2 substances, for the purpose of providing medical or pharmaceutical care
3 for their patients;

4 (b) An individual who requests the individual's own prescription
5 monitoring information;

6 (c) Health professional licensing, certification, or regulatory
7 agency or entity;

8 (d) Appropriate local, state, and federal law enforcement or
9 prosecutorial officials who are engaged in a bona fide specific
10 investigation involving a designated person;

11 (e) Authorized practitioners of the department of social and health
12 services regarding medicaid program recipients;

13 (f) Other entities under grand jury subpoena or court order; and

14 (g) Personnel of the department for purposes of administration and
15 enforcement of this chapter or chapter 69.50 RCW.

16 (5) The department may provide data to public or private entities
17 for statistical, research, or educational purposes after removing
18 information that could be used to identify individual patients,
19 dispensers, prescribers, and persons who received prescriptions from
20 dispensers.

21 (6) A dispenser or practitioner acting in good faith is immune from
22 any civil, criminal, or administrative liability that might otherwise
23 be incurred or imposed for requesting, receiving, or using information
24 from the program.

25 NEW SECTION. **Sec. 5.** The department may contract with another
26 agency of this state or with a private vendor, as necessary, to ensure
27 the effective operation of the prescription monitoring program. Any
28 contractor is bound to comply with the provisions regarding
29 confidentiality of prescription information in section 4 of this act
30 and is subject to the penalties specified in section 7 of this act for
31 unlawful acts.

32 NEW SECTION. **Sec. 6.** The department shall adopt rules to
33 implement this chapter.

34 NEW SECTION. **Sec. 7.** (1) A dispenser who knowingly fails to

1 submit prescription monitoring information to the department as
2 required by this chapter or knowingly submits incorrect prescription
3 information is subject to disciplinary action under chapter 18.130 RCW.

4 (2) A person authorized to have prescription monitoring information
5 under this chapter who knowingly discloses such information in
6 violation of this chapter is subject to civil penalty.

7 (3) A person authorized to have prescription monitoring information
8 under this chapter who uses such information in a manner or for a
9 purpose in violation of this chapter is subject to civil penalty.

10 (4) In accordance with the federal health insurance portability and
11 accountability act of 1996 and its implementing regulations, any
12 physician or pharmacist authorized to access a patient's prescription
13 monitoring may discuss or release that information to other health care
14 providers involved with the patient in order to provide safe and
15 appropriate care coordination.

16 NEW SECTION. **Sec. 8.** If any provision of this act or its
17 application to any person or circumstance is held invalid, the
18 remainder of the act or the application of the provision to other
19 persons or circumstances is not affected.

20 **Sec. 9.** RCW 42.56.360 and 2006 c 209 s 9 and 2006 c 8 s 112 are
21 each reenacted and amended to read as follows:

22 (1) The following health care information is exempt from disclosure
23 under this chapter:

24 (a) Information obtained by the board of pharmacy as provided in
25 RCW 69.45.090;

26 (b) Information obtained by the board of pharmacy or the department
27 of health and its representatives as provided in RCW 69.41.044,
28 69.41.280, and 18.64.420;

29 (c) Information and documents created specifically for, and
30 collected and maintained by a quality improvement committee under RCW
31 43.70.510 or 70.41.200, or by a peer review committee under RCW
32 4.24.250, or by a quality assurance committee pursuant to RCW 74.42.640
33 or 18.20.390, and notifications or reports of adverse events or
34 incidents made under RCW 70.56.020 or 70.56.040, regardless of which
35 agency is in possession of the information and documents;

1 (d)(i) Proprietary financial and commercial information that the
2 submitting entity, with review by the department of health,
3 specifically identifies at the time it is submitted and that is
4 provided to or obtained by the department of health in connection with
5 an application for, or the supervision of, an antitrust exemption
6 sought by the submitting entity under RCW 43.72.310;

7 (ii) If a request for such information is received, the submitting
8 entity must be notified of the request. Within ten business days of
9 receipt of the notice, the submitting entity shall provide a written
10 statement of the continuing need for confidentiality, which shall be
11 provided to the requester. Upon receipt of such notice, the department
12 of health shall continue to treat information designated under this
13 subsection (1)(d) as exempt from disclosure;

14 (iii) If the requester initiates an action to compel disclosure
15 under this chapter, the submitting entity must be joined as a party to
16 demonstrate the continuing need for confidentiality;

17 (e) Records of the entity obtained in an action under RCW 18.71.300
18 through 18.71.340;

19 (f) Except for published statistical compilations and reports
20 relating to the infant mortality review studies that do not identify
21 individual cases and sources of information, any records or documents
22 obtained, prepared, or maintained by the local health department for
23 the purposes of an infant mortality review conducted by the department
24 of health under RCW 70.05.170; (~~and~~)

25 (g) Complaints filed under chapter 18.130 RCW after July 27, 1997,
26 to the extent provided in RCW 18.130.095(1); and

27 (h) Information obtained by the department of health under chapter
28 69.-- RCW (sections 1 through 8 of this act).

29 (2) Chapter 70.02 RCW applies to public inspection and copying of
30 health care information of patients.

31 NEW SECTION. Sec. 10. Sections 1 through 8 of this act constitute
32 a new chapter in Title 69 RCW.

--- END ---